eLife is a unique collaboration between funders and practitioners of research to communicate influential discoveries in the life and biomedical sciences in the most effective way.
We are a joint initiative of the Howard Hughes Medical Institute, the Max Planck Society, and the Wellcome Trust. Along with a growing number of public and private research funders worldwide, these three organisations recognise that the communication of research results is as fundamental a component of the research process as the experiments themselves. Disseminating new findings as widely and effectively as possible maximises the value of research investments. The first step in the initiative is to establish a new, open-access venue for the most important advances — from basic biological research through to applied, translational and clinical studies.
The eLife journal will be a platform for extending the reach and influence of new discoveries and to showcase new approaches to the presentation, use, and assessment of research.
eLife is not just a journal. That’s just the beginning.
Our initiative has four aims:
- To make publishing more efficient, by providing outstanding service to authors through a swift, constructive, and fair editorial process.
- To exploit digital media in the presentation of results, by increasing their utility for further research and broadening participation to the widest possible audience.
- To drive open access, by providing an outstanding new publishing option for authors with ground-breaking research.
- To catalyse innovation in research communication, by experimentation, collaboration, and continuous improvement.
eLife Sciences Publications, Ltd is a limited liability non-profit non-stock 501(c)3 corporation incorporated in the State of Delaware, USA, with company number 5030732, and is registered in the UK with company number FC030576 and branch number BR015634 at the address 1st Floor, 24 Hills Road, Cambridge CB2 1JP.
The eLife journal (ISSN 2050-084X) is published by eLife Sciences Publications, Ltd.